Cesarini V, Guida E, Todaro F, Di Agostino S, Tassinari V, Nicolis S, Favaro R, Caporali S, Lacal PM, Botti E, Costanzo A, Rossi P, Jannini EA, Dolci S (2017) Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo. Oncogene 36(31):4508-4515. doi: 10.1038/onc.2017.53 PMID: 28368402
Objective: To investigate whether Sox2 is required during the process of melanomagenesis, melanoma growth and metastasis and in the acquisition of resistance to BRAF inhibitors (BRAFi) treatments.
Summary: The findings exclude an oncogenic function for Sox2 during melanoma development and do not support a role for this transcription factor in the acquisition of resistance to BRAFi treatments.
Usage: Immunofluorescence on melanoma cell lines
Related Products: NGFR (mu p75) Rabbit Polyclonal, affinity-purified (Cat. #AB-N01AP)